Fig. 2. Forest plots of efficacy end points (romosozumab vs placebo). (A) Standard mean difference for P1NP from baseline to month 3, (B) Standard mean difference for CTX from baseline to month 3, (C) Standard mean difference for bone mineral density of lumbar spine from baseline to month 6, (D) Standard mean difference for bone mineral density of femoral neck from baseline to month 6

Korean J Clin Pharm 2023;33:128-34 https://doi.org/10.24304/kjcp.2023.33.2.128

© 2023 Korean J Clin Pharm